First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients

INTRODUCTION: As coronavirus disease 2019 (COVID-19) outbreak globally, repurposing approved drugs is emerging as important therapeutic options. Danoprevir boosted by ritonavir (Ganovo) is a potent hepatitis C virus (HCV) protease (NS3/4A) inhibitor, which was approved and marketed in China since 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hongyi, Zhang, Zhicheng, Wang, Li, Huang, Zhihua, Gong, Fanghua, Li, Xiaodong, Chen, Yahong, Wu, Jinzi J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
4900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710192/
https://www.ncbi.nlm.nih.gov/pubmed/33235105
http://dx.doi.org/10.1097/MD.0000000000023357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710192/
https://www.ncbi.nlm.nih.gov/pubmed/33235105
http://dx.doi.org/10.1097/MD.0000000000023357

Ejemplares similares